These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 11835952)
1. The safety of triptans in the treatment of patients with migraine. Jamieson DG Am J Med; 2002 Feb; 112(2):135-40. PubMed ID: 11835952 [TBL] [Abstract][Full Text] [Related]
2. Safety and rational use of the triptans. Tepper SJ Med Clin North Am; 2001 Jul; 85(4):959-70. PubMed ID: 11480267 [TBL] [Abstract][Full Text] [Related]
5. Evaluating the safety and tolerability profile of acute treatments for migraine. Martin VT; Goldstein JA Am J Med; 2005 Mar; 118 Suppl 1():36S-44S. PubMed ID: 15841886 [TBL] [Abstract][Full Text] [Related]
6. [Triptans in migraine--here and now (15 years after they were implemented in therapy)]. Prusiński A; Rozniecki JJ Neurol Neurochir Pol; 2005; 39(4 Suppl 1):S68-77. PubMed ID: 16419574 [TBL] [Abstract][Full Text] [Related]
7. Safety profile of the triptans. Tepper SJ; Millson D Expert Opin Drug Saf; 2003 Mar; 2(2):123-32. PubMed ID: 12904112 [TBL] [Abstract][Full Text] [Related]
8. Targeting the 5-HT Huang PC; Yang FC; Chang CM; Yang CP Prog Brain Res; 2020; 255():99-121. PubMed ID: 33008517 [TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of the 5-HT1B/1D receptor agonists. Tepper SJ; Rapoport AM; Sheftell FD Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355 [TBL] [Abstract][Full Text] [Related]
10. Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future. Mitsikostas DD; Tfelt-Hansen P Cent Nerv Syst Agents Med Chem; 2012 Dec; 12(4):241-9. PubMed ID: 22934751 [TBL] [Abstract][Full Text] [Related]
12. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Ramírez Rosas MB; Labruijere S; Villalón CM; Maassen Vandenbrink A Expert Opin Pharmacother; 2013 Aug; 14(12):1599-610. PubMed ID: 23815106 [TBL] [Abstract][Full Text] [Related]
13. 5HT1F- and 5HT7-receptor agonists for the treatment of migraines. Agosti RM CNS Neurol Disord Drug Targets; 2007 Aug; 6(4):235-7. PubMed ID: 17691977 [TBL] [Abstract][Full Text] [Related]
14. Almotriptan: an effective and well-tolerated treatment for migraine pain. Pascual J Drugs Today (Barc); 2003; 39 Suppl D():31-6. PubMed ID: 15071618 [TBL] [Abstract][Full Text] [Related]
15. Profiles of 5-HT 1B/1D agonists in acute migraine with special reference to second generation agents. Deleu D; Hanssens Y Acta Neurol Belg; 1999 Jun; 99(2):85-95. PubMed ID: 10427351 [TBL] [Abstract][Full Text] [Related]
16. Patient treatment preferences and the 5-HT1B/1D agonists. Ryan RE Arch Intern Med; 2001 Nov; 161(21):2545-53. PubMed ID: 11718585 [TBL] [Abstract][Full Text] [Related]
17. Distribution of 5-HT(1B), 5-HT(1D) and 5-HT(1F) receptor expression in rat trigeminal and dorsal root ganglia neurons: relevance to the selective anti-migraine effect of triptans. Classey JD; Bartsch T; Goadsby PJ Brain Res; 2010 Nov; 1361():76-85. PubMed ID: 20833155 [TBL] [Abstract][Full Text] [Related]
18. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Shields KG; Goadsby PJ Neurobiol Dis; 2006 Sep; 23(3):491-501. PubMed ID: 16875831 [TBL] [Abstract][Full Text] [Related]
19. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Dodick D; Lipton RB; Martin V; Papademetriou V; Rosamond W; MaassenVanDenBrink A; Loutfi H; Welch KM; Goadsby PJ; Hahn S; Hutchinson S; Matchar D; Silberstein S; Smith TR; Purdy RA; Saiers J; Headache; 2004 May; 44(5):414-25. PubMed ID: 15147249 [TBL] [Abstract][Full Text] [Related]